Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.

Read more…

spot_imgspot_img

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here